Report for Q3 2026
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
(603456)"Zhejiang Jiuzhou Pharmaceutical Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 603456 ·
6ix is reading this filing.
View original source (Shanghai Stock Exchange)Zhejiang Jiuzhou Pharmaceutical Co., Ltd. on 6ix
Earlier from Zhejiang Jiuzhou Pharmaceutical
- (603456)"Zhejiang Jiuzhou Pharmaceutical Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
- (603456)"Zhejiang Jiuzhou Pharmaceutical Co., Ltd."Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2026
- (603456)"Zhejiang Jiuzhou Pharmaceutical Co., Ltd."Announcement on Resolutions of the 1st Meeting of the 9th Board of Directors
- (603456)"Zhejiang Jiuzhou Pharmaceutical Co., Ltd."Announcement on Receipt of EU GMP Certificate by Wholly-owned Subsidiary
- (603456)"Zhejiang Jiuzhou Pharmaceutical Co., Ltd."Announcement on Progress of the Wholly-owned Subsidiary's Participation in the Investment in Jiaxing Longfeng Venture Capital Partnership (Limited Partnership)
Follow Zhejiang Jiuzhou Pharmaceutical into a list and get an email when it puts out news.
Follow Zhejiang Jiuzhou Pharmaceutical